Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Iterum Therapeutics plc Director's Dealing 2018

Aug 28, 2018

34796_dirs_2018-08-28_2f87d5f0-6a06-4e68-8427-79f50694c1da.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Iterum Therapeutics plc (ITRM)
CIK: 0001659323
Period of Report: 2018-08-24

Reporting Person: Dunne Michael W. (Chief Scientific Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2018-08-24 Ordinary Shares P 500 $10.00 Acquired 146958 Direct
2018-08-27 Ordinary Shares P 500 $10.00 Acquired 147458 Direct